Mydecine Innovations says its R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds

Mydecine Innovations Group Inc. (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) said its R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds with pharmacological potential in mushrooms. 

Over the past months, Mydecine noted that the team has screened over 25 mushroom species, including various varieties of p. cubensis, and has selected and analyzed over 40 unique compounds found throughout the various species.

Of these compounds, a large majority appear to have never been reported before and could be vital to the critical effects of naturally-sourced mushrooms on human health and wellbeing as well as synergistic effects with pure psilocybin. 

READ: Mydecine gets Health Canada nod for expanding cultivation capabilities for psilocybin producing mushrooms

“Most mushrooms, especially the noxious species, have not been investigated for their chemical components,” said Mydecine senior scientist, Duff Sloley in a statement. “Most of these compounds are evolved to protect the mushroom’s fruiting body from predation by insects, nematodes and bacteria and are complex and metabolically expensive to produce. Since these compounds are evolved to affect biological systems and aspects of metabolic pathways, they stand a higher chance of proving to be useful pharmaceuticals.”

“As a consequence, studies of the structural, chemical, and possibly fortuitous pharmacological properties of these unknown compounds may lead to the development of beneficial pharmacological treatments for a number of disease states,” he added. 

Dr Sloley holds a PhD in Biology from the University of Waterloo and has over 35 years of experience in analytical research and product development including positions at the University of Saskatchewan’s Neuropsychiatric Research Unit, Novokin Biotech, Sinoveda, and Radient Technologies. His specialties include comparative neurobiology with a focus on neurotransmitter identification, metabolism and disruption as well as botanical composition.

He has extensive experience working in analytical biochemistry in a GLP setting including HPLC, LCMS/MS, UV absorbance and fluorescent detection. Additionally, Dr Sloley is an active member of the Alberta Mycological Society and will be instrumental in characterizing and discovering new potent compounds as well as working with Society to source novel fungi. 

“We have seen accelerated progress through Mydecine’s fully integrated research and cultivation facilities,” commented Josh Bartch, CEO of Mydecine. “These tremendous advances in our treatment development could not have been possible without our state-of-the-art R&D center and world-class research team.

“We not only have the ability to discover new compounds, but test them for efficacy, manufacture them for clinical research through a scientific rigor. This end-to-end capability is a critical to successful drug development and sets Mydecine apart,” Bartch concluded.

Contact the author at [email protected]

Story by ProactiveInvestors